-

QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter of 2022.

Press release date / time: Wednesday, July 27, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Thursday, July 28, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.

Three options for joining the conference call

Register for call back connection

 

Click here:

Connect Me

 

Service available 15 minutes before call start

Dial-in by phone

 

 

+1 646 828 8075 (U.S.)

+44 (0)330 165 4012 (UK)

+49 (0)69 22222 5197 (GER)

 

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

 

Conference ID: 3332305

 

Access the audio webcast

 

Click here:

Access Webcast

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1556677&tp_key=b55d95ed6e

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2022, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Contacts

John Gilardi
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

QIAGEN N.V.

FWB:QIA
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)

Release Summary
QIAGEN N.V. to release results for Q2 2022 and hold Webcast
Release Versions

Contacts

John Gilardi
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
Email: ir@qiagen.com

More News From QIAGEN N.V.

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and manage ordering support through a single conversational interface. “Researchers today are navigating growing scientific complexity, increasing volumes of data and expanding workflow choices,”...

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

VENLO, Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery. The integration is designed to help pharmaceutical and biot...

QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced proposals for its 2026 Annual General Meeting, including plans to appoint co-founder and former Chief Executive Officer Dr. Metin Colpan as Honorary Chairman, the continued renewal of the Supervisory Board and increased returns to shareholders. The Annual General Meeting, to be held on June 24, 2026, in Venlo, the Netherlands, will include proposals to elect Robert McMahon as a new member of...
Back to Newsroom